Zacks: Analysts Expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Will Announce Earnings of -$0.38 Per Share

Wall Street analysts expect that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will announce earnings per share (EPS) of ($0.38) for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.45). Tetraphase Pharmaceuticals posted earnings per share of ($0.18) during the same quarter last year, which indicates a negative year-over-year growth rate of 111.1%. The company is scheduled to report its next quarterly earnings results on Thursday, August 1st.

On average, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.50) per share for the current fiscal year, with EPS estimates ranging from ($1.78) to ($1.29). For the next financial year, analysts anticipate that the business will report earnings of ($1.13) per share, with EPS estimates ranging from ($1.68) to ($0.81). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.03. Tetraphase Pharmaceuticals had a negative return on equity of 80.01% and a negative net margin of 383.19%. The company had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.93 million.

A number of research analysts have issued reports on TTPH shares. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, May 12th. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 26th. ValuEngine cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 6th. Finally, Piper Jaffray Companies decreased their target price on Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating on the stock in a research report on Friday, March 15th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $4.08.

Tetraphase Pharmaceuticals stock traded down $0.01 during midday trading on Thursday, reaching $0.73. The company’s stock had a trading volume of 446,035 shares, compared to its average volume of 608,399. Tetraphase Pharmaceuticals has a 52 week low of $0.71 and a 52 week high of $4.49. The company has a quick ratio of 7.10, a current ratio of 7.28 and a debt-to-equity ratio of 0.53. The stock has a market cap of $41.78 million, a PE ratio of -0.53 and a beta of 2.90.

Institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its position in Tetraphase Pharmaceuticals by 890.0% in the fourth quarter. Deutsche Bank AG now owns 1,040,447 shares of the biopharmaceutical company’s stock valued at $1,174,000 after acquiring an additional 935,349 shares during the last quarter. 683 Capital Management LLC grew its position in Tetraphase Pharmaceuticals by 10.6% in the fourth quarter. 683 Capital Management LLC now owns 790,571 shares of the biopharmaceutical company’s stock valued at $893,000 after acquiring an additional 75,474 shares during the last quarter. Two Sigma Advisers LP grew its position in Tetraphase Pharmaceuticals by 50.2% in the fourth quarter. Two Sigma Advisers LP now owns 221,000 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 73,900 shares during the last quarter. SG Americas Securities LLC bought a new position in Tetraphase Pharmaceuticals in the fourth quarter valued at about $69,000. Finally, Rhumbline Advisers grew its holdings in shares of Tetraphase Pharmaceuticals by 40.6% during the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 21,089 shares during the last quarter. Hedge funds and other institutional investors own 38.67% of the company’s stock.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: What does a bar chart display?

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.